Published in J Hepatol on November 03, 2014
Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma | NCT01924624
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer | NCT01956864
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell (2016) 1.14
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med (2017) 0.96
Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.91
Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int (2015) 0.83
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. J Virol (2015) 0.81
A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. J Hepatol (2015) 0.79
Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol (2015) 0.77
The role of viral co-infection in HIV-associated non-AIDS-related cancers. Curr HIV/AIDS Rep (2015) 0.76
The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget (2016) 0.76
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol (2016) 0.75
How Hepatitis C Virus Leads to Hepatocellular Carcinoma: A Network-Based Study. Hepat Mon (2016) 0.75
Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention. World J Hepatol (2016) 0.75
Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) (2015) 0.75
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol (2017) 0.75
Circulating microRNAs for early detection of hepatitis B-related hepatocellular carcinoma. Hepatobiliary Surg Nutr (2016) 0.75
HEPATITIS C VIRUS CORE PROTEIN MODULATES ENDOGLIN (CD105) SIGNALING PATHWAY FOR LIVER PATHOGENESIS. J Virol (2017) 0.75
Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity. Redox Biol (2017) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Cancer genome landscapes. Science (2013) 25.33
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell (2004) 6.48
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A (2005) 5.31
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med (2011) 4.98
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4.48
Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell (2013) 4.45
Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol (2008) 4.29
Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A (1997) 3.88
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst (2012) 3.69
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med (2000) 3.44
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med (2013) 3.35
Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30
NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2011) 3.28
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet (2011) 3.19
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J (2002) 3.06
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 3.00
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol (2000) 2.68
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med (2002) 2.68
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
The use of genomics in clinical trial design. Clin Cancer Res (2008) 2.61
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology (2009) 2.43
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology (2007) 2.42
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol (2002) 2.39
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A (2005) 2.28
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology (2009) 2.16
Adipokines in liver diseases. Hepatology (2009) 2.14
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther (2009) 2.11
Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet (2011) 2.09
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A (1999) 2.03
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One (2012) 1.93
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology (2005) 1.90
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol (2013) 1.88
Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol (2013) 1.87
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol (2010) 1.86
Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology (2007) 1.85
Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology (2009) 1.84
A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology (2014) 1.81
A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology (2009) 1.78
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology (2009) 1.73
Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol (2001) 1.73
Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology (2004) 1.73
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med (2003) 1.70
Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res (2014) 1.68
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature (2014) 1.64
Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med (2014) 1.64
Type I interferon response and innate immune sensing of cancer. Trends Immunol (2012) 1.59
Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59
PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest (2008) 1.55
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology (2011) 1.52
Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol (2003) 1.52
Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology (2010) 1.51
Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol (2013) 1.48
Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol (2003) 1.46
Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol (2009) 1.43
MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun (2011) 1.41
Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol (2013) 1.39
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology (2007) 1.38
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest (2013) 1.37
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol (2010) 1.36
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol (2010) 1.35
Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA (2000) 1.33
Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int (2007) 1.30
Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology (2005) 1.30
Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology (2006) 1.29
Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A (2005) 1.29
Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol (2007) 1.28